Ractigen Therapeutics obtains $30M to develop RNAa platform

By The Science Advisory Board staff writers

January 28, 2022 -- Ractigen Therapeutics has received $30 million in a series A financing round. Ractigen will use the proceeds to advance several programs from the preclinical to clinical phase as well as to scale up its oligonucleotide manufacturing capabilities.

This latest round follows an $18 million series A investment the company obtained in February 2021.

Ractigen Therapeutics is an early-stage pharmaceutical company focused on the development of technologies to restore gene expression in silenced therapeutic genes. The RNAa technology, according to the company, allows for targeted activation of endogenous gene expression, enabling its use in the treatment of various genetic disorders ranging from monogenic diseases to liver-related indications and cancer.

The company was founded in 2017 by Dr. Long-Cheng Li, Robert Place, PhD, and Moo Rim Kang, PhD.

The series A round was led by SDIC Venture Capital with participation from Eisai, LC Ventures, CSSD Capital, and Xiang He Capital.

Copyright © 2022 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter